




**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listing of claims in this application.**

**Please cancel claims 17 to 28 without prejudice or disclaimer.**

Claim 1. (previously presented): A compound of Formula I:



or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR<sub>a</sub>, wherein R<sub>a</sub> is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

A<sub>1</sub> is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>a</sub>, -COOR<sub>a</sub>, -CONR<sub>a</sub>R<sub>b</sub>, -NHCOR<sub>a</sub>R<sub>b</sub>, -NHSO<sub>2</sub>R<sub>a</sub>, -SO<sub>2</sub>R<sub>a</sub>, -SO<sub>3</sub>R<sub>a</sub> or -SO<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R<sub>1</sub> is

hydrogen, alkyl, hydroxy or alkoxy;

R<sub>2</sub> is

hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R<sub>3</sub> is

a direct link or  
C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> thioalkyl, C<sub>1-6</sub> hydroxyalkyl or C<sub>1-6</sub> carboxyalkyl; and

A<sub>2</sub> is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C<sub>1-4</sub> alkyl, amino, aminoalkyl, halogen, hydroxy, -CF<sub>3</sub>, alkoxy, aryloxy, arylalkoxy, -OCF<sub>3</sub>, -COR<sub>c</sub>, -COOR<sub>c</sub>, -CONR<sub>c</sub>R<sub>d</sub>, -N(R<sub>1</sub>)COR<sub>c</sub>, -SO<sub>2</sub>R<sub>c</sub>, -SO<sub>3</sub>R<sub>c</sub> or -SO<sub>2</sub>NR<sub>c</sub>R<sub>d</sub>;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>c</sub>, -COOR<sub>c</sub>, -CONR<sub>c</sub>R<sub>d</sub>, -NHCOR<sub>c</sub>R<sub>d</sub>, NHSO<sub>2</sub>R<sub>c</sub>, -SO<sub>2</sub>R<sub>c</sub>, -SO<sub>3</sub>R<sub>c</sub> or -SO<sub>2</sub>NR<sub>c</sub>R<sub>d</sub>; or

-COR<sub>c</sub>, -COOR<sub>c</sub> or -CONR<sub>c</sub>R<sub>d</sub>, wherein

R<sub>c</sub> and R<sub>d</sub> are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 2. (previously presented): A compound of Formula II:



or pharmaceutically acceptable salt thereof, wherein

R is

-COR<sub>a</sub>, -CONR<sub>a</sub>R<sub>b</sub>, -SO<sub>2</sub>R<sub>a</sub> or -PO<sub>3</sub>R<sub>a</sub>R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;

A<sub>1</sub> is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>c</sub>, -COOR<sub>c</sub>, -CONR<sub>c</sub>R<sub>d</sub>, -NHCOR<sub>c</sub>R<sub>d</sub>, -NHSO<sub>2</sub>R<sub>c</sub>, -SO<sub>2</sub>R<sub>c</sub>, -SO<sub>3</sub>R<sub>c</sub> or -SO<sub>2</sub>NR<sub>c</sub>R<sub>d</sub>,

wherein  $R_c$  and  $R_d$  are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

$R_1$  is  
hydrogen, alkyl, hydroxy or alkoxy;

$R_2$  is  
hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

$R_3$  is  
a direct link or  
 $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  thioalkyl,  $C_{1-6}$  hydroxyalkyl or  $C_{1-6}$  carboxyalkyl; and


$A_2$  is  
phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of  $C_{1-4}$  alkyl, amino, aminoalkyl, halogen, hydroxy,  $-CF_3$ , alkoxy, aryloxy, arylalkoxy,  $-OCF_3$ ,  $-COR_e$ ,  $-COOR_e$ ,  $-CONR_eR_f$ ,  $-N(R_1)COR_e$ ,  $-SO_2R_e$ ,  $-SO_3R_e$  or  $-SO_2NR_eR_f$ ;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with  $C_{1-6}$  alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy,  $-CF_3$ ,  $-OCF_3$ ,  $-COR_e$ ,  $-COOR_e$ ,  $-CONR_eR_f$ ,  $-NHCOR_eR_f$ ,  $NHSO_2R_a$ ,  $-SO_2R_a$ ,  $-SO_3R_a$  or  $-SO_2NR_aR_b$ ; or

$-COR_e$ ,  $-COOR_e$  or  $-CONR_eR_f$ , wherein

$R_e$  and  $R_f$  are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 3. (previously presented): A compound of Formula III:



or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR<sub>a</sub>, wherein R<sub>a</sub> is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;


A<sub>1</sub> is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>a</sub>, -COOR<sub>a</sub>, -CONR<sub>a</sub>R<sub>b</sub>, -NHCOR<sub>a</sub>R<sub>b</sub>, -NHSO<sub>2</sub>R<sub>a</sub>, -SO<sub>2</sub>R<sub>a</sub>, -SO<sub>3</sub>R<sub>a</sub> or -SO<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R<sub>1</sub> is

hydrogen, alkyl, hydroxy or alkoxy; and

R<sub>2</sub> is



wherein

R<sub>c</sub> and R<sub>d</sub> are independently hydrogen or alkyl;

X is N, O or S; and


A<sub>2</sub> is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C<sub>1-4</sub> alkyl, amino, aminoalkyl, halogen, hydroxy, -CF<sub>3</sub>, alkoxy, aryloxy, arylalkoxy, -OCF<sub>3</sub>, -COR<sub>e</sub>, -COOR<sub>e</sub>, -CONR<sub>e</sub>R<sub>f</sub>, -N(R<sub>1</sub>)COR<sub>e</sub>, -SO<sub>2</sub>R<sub>e</sub>, -SO<sub>3</sub>R<sub>e</sub> or -SO<sub>2</sub>NR<sub>e</sub>R<sub>f</sub>; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>e</sub>, -COOR<sub>e</sub>, -CONR<sub>e</sub>R<sub>f</sub>, -NHCOR<sub>e</sub>R<sub>f</sub>, NHSO<sub>2</sub>R<sub>e</sub>, -SO<sub>2</sub>R<sub>e</sub>, -SO<sub>3</sub>R<sub>e</sub> or -SO<sub>2</sub>NR<sub>e</sub>R<sub>f</sub>, wherein

R<sub>e</sub> and R<sub>f</sub> are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 4. (previously presented): A compound of Formula IV:



or pharmaceutically acceptable salt thereof, wherein

R is

-COR<sub>a</sub>, -CONR<sub>a</sub>R<sub>b</sub>, -SO<sub>2</sub>R<sub>a</sub> or -PO<sub>3</sub>R<sub>a</sub>R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;


A<sub>1</sub> is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C<sub>1-6</sub> alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COR<sub>c</sub>, -COOR<sub>c</sub>, -CONR<sub>c</sub>R<sub>d</sub>, -NHCOR<sub>c</sub>R<sub>d</sub>, -NHCO<sub>2</sub>R<sub>c</sub>, -SO<sub>2</sub>R<sub>c</sub>, -SO<sub>3</sub>R<sub>c</sub> or -SO<sub>2</sub>NR<sub>c</sub>R<sub>d</sub>, wherein R<sub>c</sub> and R<sub>d</sub> are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R<sub>1</sub> is

hydrogen, alkyl, hydroxy or alkoxy; and

$R_2$  is



wherein

$R_e$  and  $R_f$  are independently hydrogen or alkyl;

X is N, O or S; and

$A_2$  is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of  $C_{1-4}$  alkyl, amino, aminoalkyl, halogen, hydroxy,  $-CF_3$ , alkoxy, aryloxy, arylalkoxy,  $-OCF_3$ ,  $-COR_g$ ,  $-COOR_g$ ,  $-CONR_gR_h$ ,  $-N(R_1)COR_g$ ,  $-SO_2R_g$ ,  $-SO_3R_g$  or  $-SO_2NR_gR_h$ ; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with  $C_{1-6}$  alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy,  $-CF_3$ ,  $-OCF_3$ ,  $-COR_g$ ,  $-COOR_g$ ,  $-CONR_gR_h$ ,  $-NHCOR_gR_h$ ,  $NHSO_2R_g$ ,  $-SO_2R_g$ ,  $-SO_3R_g$  or  $-SO_2NR_gR_h$ , wherein

$R_g$  and  $R_h$  are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 5. (original): A compound of claim 1, wherein

$A_1$  is




wherein  $R_a$  and  $R_b$  are independently -H,  $-C_{1-6}$  alkyl,  $-CO_2$ -alkyl or  $-CO_2-CH_2CH_2NH_2$ ;

$R_1$  is -H;

$R_2$  is

-H, -Me, -Et,




wherein  $R_c$  is alkyl;

$R_3$  is

$-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH(CH_3)-$ ,  $-C(CH_3)_2-$ ,  $-CH(CH_2OH)-$  or  $-CH(CH_2CH_2COOH)-$ ; and

$A_2$  is



wherein X is O or S.

Claim 6. (previously presented): A compound of Formula I according to claim 1,  
selected from

4-(Benzothiazol-6-ylamino)-6-(ethyl-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(methyl-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(benzylamino)-[1,3,5]triazin-2-ol;  
(R)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;  
(S)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;  
(R)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
(S)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
(R)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
(S)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(methyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(ethyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2-chloro-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2-fluoro-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(pyridin-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2,6-difluoro-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[methyl-(2-pyridin-2-yl-ethyl)amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[pyridin-2-ylmethyl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[benzyl-(1-benzyl-pyrrolidin-3-yl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(3-fluoro-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2-chloro-6-methyl-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(N'-methyl-N'-phenyl-hydrazino)-[1,3,5]triazin-2-ol;  
4-(benzothiazol-6-ylamino)-6-[(pyridin-4-ylmethyl)-amino]-[1,3,5]triazin-2-ol;  
4-Benzothiazol-6-ylamino)-6-(2-pyridin-3-yl-ethylamino)-[1,3,5]triazin-2-ol;  
4-Benzothiazol-6-ylamino)-6-(1-phenyl-propylamino)-[1,3,5]triazin-2-ol;



4-(Benzothiazol-6-ylamino)-6-(2-pyridin-2-yl-ethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(1-naphthalen-1-yl-ethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(3-hydroxymethyl-phenylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(quinolin-5-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(4-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(1H-indazol-6-yl)-methylamino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(6-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(3-hydroxy-phenylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[2-(2-hydroxyethyl)-phenylamino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(5-thiophen-2-yl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol; 4-  
(Benzothiazol-6-ylamino)-6-(2-phenyl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2,4-difluoro-benzylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-phenylamino-[1,3,5]triazin-2-ol;  
4-(1H-Indazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(2-hydroxy-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(1H-Indazol-5-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-7-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(furan-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(furan-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[(thiophen-3-yl-methyl)amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-(benzyl-pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ol;  
3-{[4-(Benzothiazol-6-ylamino)-6-hydroxy-[1,3,5]triazin-2-yl]-benzylamino}-propane-1,2-diol;  
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-morpholin-4-ylpropyl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-{benzyl-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-  
[1,3,5]triazin-2-ol;

4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-dimethylamino-propyl)-amino]-[1,3,5]triazin-2-ol;  
4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-piperazin-1-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-  
(Benzothiazol-6-ylamino)-6-[benzyl-(2-morpholin-4-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-  
(Benzothiazol-6-ylamino)-6-[benzyl-(2-dimethylamino-ethyl)-amino]-[1,3,5]triazin-2-ol; 4-(2-  
Amino-benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; 4-(1-  
Methyl-1-phenylethylamino)-6-(quinolin-6-ylamino)-[1,3,5]triazin-2-ol;  
4-(Quinolin-6-ylamino)-6-(N-ethylbenzylamino)-[1,3,5]triazin-2-ol;  
4-(Quinolin-6-ylamino)-6-(N-methylbenzylamino)-[1,3,5]triazin-2-ol;  
4-(Quinolin-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;  
N-[4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-yl]-  
hydroxylamine;  
or a pharmaceutically acceptable salt thereof.

Claim 7. (previously presented): A compound of Formula III according to claim 3,  
selected from

4-(Benzothiazol-6-yl-amino)-6-(2-methyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(2-benzyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(2,6-dimethyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(2,5-dimethyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(3-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(3-methyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;  
4-(Benzothiazol-6-yl-amino)-6-(morpholin-4-yl)-[1,3,5]triazine-2-ol;  
or a pharmaceutically acceptable salt thereof.

Claim 8. (original): A pharmaceutical composition, comprising a compound of any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

Claim 9. (original): A pharmaceutical composition, comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

Claim 10. (original): A pharmaceutical composition, comprising a compound of claim 6 or 7 and a pharmaceutically acceptable carrier.

Claim 11. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine; and
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

Claim 12. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of :

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and

d) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)- [1,3,5]triazine, respectively.

Claim 13. (original): A method of claim 11 or 12, wherein the displaceable groups are chlorines.

Claim 14. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

Claim 15. (original): A method of preparing the compounds of Formulae I and III where R is -NHOH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with hydroxylamine under acidic conditions to give a 4,6-diamino-([1,3,5]triazin-2-yl)-hydroxylamine.

Claim 16. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine;

cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and

dd) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)-[1,3,5]triazine, respectively.

Claims 17 to 30 (cancelled).

Claim 31. (previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

Claim 32. (previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

Claim 33. ((previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

Claims 34 to 42. (cancelled).

Claim 43. (original): A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier and from about 0.5 mg to about 10 g of at least one compound of any one of claims 1 to 7.

Claim 44. (original): A dosage form according to claim 43 adapted for parenteral or oral administration.